Equity Profile

CGON

CG Oncology, Inc.

Health CareBiotechnology$6.4B

Aug7Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is crucial for understanding the company's profitability and performance relative to expectations.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative cancer therapies. Operating in the Health Care sector, it aims to address significant unmet medical needs in oncology, which is a major theme in today's healthcare landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In Q1-2026, CG Oncology reported an EPS of -$0.71, missing estimates by 23%. The stock reacted positively, gaining 0.64% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about CG Oncology's upcoming earnings, especially given the volatility in previous quarters.

Bull Case

If the company can demonstrate progress in clinical trials and improve its EPS, it could signal strong future growth potential.

Bear Case

However, continued losses and missed expectations could lead to further declines in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

The outcome of these trials could significantly impact future revenue and investor confidence.

How does management plan to address the recent EPS misses?

Understanding the strategy to improve profitability is crucial for investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of upcoming clinical trial results, which could lead to a significant positive shift in sentiment.

Supporting Evidence

Options are pricing a 36.98% move, indicating high uncertainty that may not align with historical performance.

The company's recent stock movements suggest that investors are still optimistic despite recent EPS misses.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery against the backdrop of recent performance and high expectations.

Bull Confirmed If

A positive update on clinical trial results could confirm the bull case.

Bear Confirmed If

Continued EPS losses without a clear path to profitability would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±36.98%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty or strong sentiment about the upcoming earnings.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.8%, with a raw directional average of -1.5% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests a potential stock increase of around 0.1%, confirming optimism about future growth.

In-Line / Cautious

An in-line report may lead to muted reactions as the market digests management's commentary on future plans.

Miss

If the company misses again, history suggests a decline of around 0.79%, reinforcing bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Management's strategy for improving profitability and addressing EPS misses.
3Any new partnerships or collaborations that could enhance growth.
4Insights into market demand for their products and therapies.
5Future guidance on revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

BP p.l.c.

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is crucial for understanding the company's profitability and performance relative to expectations.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In Q1-2026, CG Oncology reported an EPS of -$0.71, missing estimates by 23%. The stock reacted positively, gaining 0.64% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about CG Oncology's upcoming earnings, especially given the volatility in previous quarters.

Bull Case

If the company can demonstrate progress in clinical trials and improve its EPS, it could signal strong future growth potential.

Bear Case

However, continued losses and missed expectations could lead to further declines in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

The outcome of these trials could significantly impact future revenue and investor confidence.

How does management plan to address the recent EPS misses?

Understanding the strategy to improve profitability is crucial for investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of upcoming clinical trial results, which could lead to a significant positive shift in sentiment.

Supporting Evidence

Options are pricing a 36.98% move, indicating high uncertainty that may not align with historical performance.

The company's recent stock movements suggest that investors are still optimistic despite recent EPS misses.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery against the backdrop of recent performance and high expectations.

Bull Confirmed If

A positive update on clinical trial results could confirm the bull case.

Bear Confirmed If

Continued EPS losses without a clear path to profitability would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±36.98%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty or strong sentiment about the upcoming earnings.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests a potential stock increase of around 0.1%, confirming optimism about future growth.

In-Line / Cautious

An in-line report may lead to muted reactions as the market digests management's commentary on future plans.

Miss

If the company misses again, history suggests a decline of around 0.79%, reinforcing bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Management's strategy for improving profitability and addressing EPS misses.
3Any new partnerships or collaborations that could enhance growth.
4Insights into market demand for their products and therapies.
5Future guidance on revenue expectations.